381 related articles for article (PubMed ID: 29713055)
1. A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis.
Pavan S; Meyer-Schaller N; Diepenbruck M; Kalathur RKR; Saxena M; Christofori G
Oncogene; 2018 Aug; 37(31):4197-4213. PubMed ID: 29713055
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
Liu F; Zhang H; Song H
Oncol Rep; 2017 Jan; 37(1):83-90. PubMed ID: 27878304
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
[TBL] [Abstract][Full Text] [Related]
4. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.
Bhatt AB; Patel S; Matossian MD; Ucar DA; Miele L; Burow ME; Flaherty PT; Cavanaugh JE
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572742
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia.
Richards EJ; Zhang G; Li ZP; Permuth-Wey J; Challa S; Li Y; Kong W; Dan S; Bui MM; Coppola D; Mao WM; Sellers TA; Cheng JQ
J Biol Chem; 2015 Mar; 290(11):6857-67. PubMed ID: 25605728
[TBL] [Abstract][Full Text] [Related]
8. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
9. Foxf2 plays a dual role during transforming growth factor beta-induced epithelial to mesenchymal transition by promoting apoptosis yet enabling cell junction dissolution and migration.
Meyer-Schaller N; Heck C; Tiede S; Yilmaz M; Christofori G
Breast Cancer Res; 2018 Oct; 20(1):118. PubMed ID: 30285803
[TBL] [Abstract][Full Text] [Related]
10. miR-143 suppresses epithelial-mesenchymal transition and inhibits tumor growth of breast cancer through down-regulation of ERK5.
Zhai L; Ma C; Li W; Yang S; Liu Z
Mol Carcinog; 2016 Dec; 55(12):1990-2000. PubMed ID: 26618772
[TBL] [Abstract][Full Text] [Related]
11. MEK5/ERK5 pathway: the first fifteen years.
Drew BA; Burow ME; Beckman BS
Biochim Biophys Acta; 2012 Jan; 1825(1):37-48. PubMed ID: 22020294
[TBL] [Abstract][Full Text] [Related]
12. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
[TBL] [Abstract][Full Text] [Related]
13. The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target.
Simões AE; Rodrigues CM; Borralho PM
Drug Discov Today; 2016 Oct; 21(10):1654-1663. PubMed ID: 27320690
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
[TBL] [Abstract][Full Text] [Related]
15. Targeted Avenues for Cancer Treatment: The MEK5-ERK5 Signaling Pathway.
Pereira DM; Rodrigues CMP
Trends Mol Med; 2020 Apr; 26(4):394-407. PubMed ID: 32277933
[TBL] [Abstract][Full Text] [Related]
16. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling.
Mansour MA; Hyodo T; Ito S; Kurita K; Kokuryo T; Uehara K; Nagino M; Takahashi M; Hamaguchi M; Senga T
FEBS J; 2015 Apr; 282(8):1394-405. PubMed ID: 25662172
[TBL] [Abstract][Full Text] [Related]
17. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
Cristea S; Coles GL; Hornburg D; Gershkovitz M; Arand J; Cao S; Sen T; Williamson SC; Kim JW; Drainas AP; He A; Cam LL; Byers LA; Snyder MP; Contrepois K; Sage J
Cancer Res; 2020 Mar; 80(6):1293-1303. PubMed ID: 31969375
[TBL] [Abstract][Full Text] [Related]
18. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT).
Serrano I; McDonald PC; Lock FE; Dedhar S
Oncogene; 2013 Jan; 32(1):50-60. PubMed ID: 22310280
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming during epithelial to mesenchymal transition under the control of TGFβ.
Tan EJ; Olsson AK; Moustakas A
Cell Adh Migr; 2015; 9(3):233-46. PubMed ID: 25482613
[TBL] [Abstract][Full Text] [Related]
20. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.
Simões AE; Pereira DM; Gomes SE; Brito H; Carvalho T; French A; Castro RE; Steer CJ; Thibodeau SN; Rodrigues CM; Borralho PM
Cell Death Dis; 2015 Apr; 6(4):e1718. PubMed ID: 25855966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
